IMMX: Ascending Triangle detected on 9 Mar 2026

IMMX is forming an ascending triangle following FDA Breakthrough Therapy Designation for lead candidate NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results. At $9.29, the stock trades just above 9.02 resistance with 8.3 support forming the triangle base. Structure score of 15.0 and breakout score of 13.0 indicate clean consolidation with strong volume confirmation (12.0). The 92.0 overall score and 77.41% win probability suggest a high-quality chart pattern. Current volume of 1.11M shares runs 1.48x the 20-day average, showing institutional accumulation into the setup.

The FDA granted Breakthrough Therapy Designation to NXC-201 for relapsed/refractory AL amyloidosis based on positive NEXICART-2 Phase 2 interim results, with final data expected in 2026 and planned BLA submission this year. NXC-201 demonstrated a 75% complete response rate by independent review committee, with potential CR to reach 95% pending additional assessments. The company appointed Michael Grabow as Chief Commercial Officer in November 2025, who previously led MODEYSO launch at Chimerix before its $935 million acquisition by Jazz. Management is presenting at Leerink Partners Global Healthcare Conference (March 8-11) and Citizens Life Sciences Conference (March 10-11) in Miami, hosting one-on-one investor meetings. Analyst consensus rates IMMX as "Strong Buy" with $13 price target representing 74.97% upside.

An ascending triangle breakout above 9.02 resistance would target 9.76 conservative, with potential extension to 10.50 based on pattern amplitude. Historical data shows 77.41% probability of successful breakout if volume remains elevated above 750k shares. The measured move assumes two weeks to breakout confirmation. Invalidation occurs at 8.3 support—a close below this level signals pattern failure. Volume confirmation is critical; breakouts on less than 1.25x average volume show elevated false-break risk in clinical biotech stocks.

Earnings announcement is scheduled for March 23, 2026, just 14 days from pattern formation—timing creates potential event risk before breakout confirmation. RSI of 71.79 indicates overbought conditions; pullback to support is possible. The company faces substantial risks including potential poorer-than-expected efficacy in late-stage trials and unanticipated safety concerns. Sector regime is bearish (-0.24 regime score), creating macro headwinds for biotech. Stock has already surged 123.86% in three months and 15.12% in one week—rapid gains increase pullback probability. Beta of 0.96 provides limited downside protection. BLA submission timeline in 2026 introduces regulatory execution risk; any setback in NEXICART-2 final data or BLA could trigger sharp reversal.